Torna ai risultati
Scheda bibliografica · Consultazione e accesso
Artículo

Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies

Scheidegger, Marco A. et al · Biochimica et Biophysica Acta (BBA) - General Subjects · 2026

Accesso aperto disponibile
Lettura rapida. Controlla i dati essenziali della risorsa e accedi al contenuto con il pulsante principale. La scheda mostra solo le informazioni necessarie per identificare, citare e aprire l’opera.

Accesso alla risorsa

Apri il contenuto dall’opzione principale o scegli un’altra fonte disponibile.

RI ITBA RI ITBA OAI-PMH
Entrar por RI ITBA
Accesso principale

Accesso aperto disponibile

Recurso identificado como acceso abierto, sin confirmar automáticamente si es texto completo directo.
Apri risorsa

Riepilogo

Descripción general del contenido del recurso.

"The diverse repertoire of cell surface glycans, generated by the coordinated activity of glycosyltransferases and glycosidases, encodes critical biological information that is interpreted by glycan-binding proteins including galectins. Galectin-1 (GAL1), a member of this family, plays key roles across multiple hallmarks of cancer, including angiogenesis and immune evasion, driving resistance to anti-angiogenic and immunotherapeutic strategies through glycosylation-dependent mechanisms. Here, we first review the contribution of GAL1–glycan interactions to therapeutic resistance in cancer, with a particular focus on anti-angiogenic therapies and immunotherapy, and discuss the central role of glycosyltransferases in shaping these responses. While the biosynthesis of ‘GAL1-permissive’ glycans has been extensively characterized, the contribution of post-synthetic glycan remodeling to GAL1-driven therapeutic resistance remains uncertain. To explore mechanisms underlying GAL1-mediated resistance, we investigated whether tumor- or stromal-derived sialidases (NEU1 or NEU3) modulate sensitivity to vascular endothelial growth factor (VEGF)–targeted therapies by unmasking GAL1-binding glyco-epitopes. In the second part of the study, we present original in vivo experiments using gain- and loss-of-function approaches, demonstrating that, at least in our experimental settings, sialidases do not contribute to resistance to anti-VEGF treatment. Finally, bioinformatic analyses of patient datasets revealed differential regulation of GAL1, as well as specific glycosyltransferases, in patients responding or not to anti-VEGF or anti-PD-1 therapies. Collectively, these findings indicate that glycosyltransferases, particularly MGAT5, GCNT1, and ST6GAL1, coordinately shape the GAL1-specific glycome in settings of therapeutic resistance, whereas glycan remodeling by endogenous sialidases does not play a major role. Whether sialidases influence GAL1-dependent functions in other contexts remains to be explored".

Come citare

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

Scheidegger, M. A. E. A. (2026). Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies. https://doi.org/10.1016/j.bbagen.2026.130931

MLA

Scheidegger, Marco A. et al. "Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies." 2026. https://doi.org/10.1016/j.bbagen.2026.130931.

Chicago

Scheidegger, Marco A. et al. 2026. "Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies.". https://doi.org/10.1016/j.bbagen.2026.130931.

Harvard

Scheidegger, M. A. E. A. 2026, Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies, Biochimica et Biophysica Acta (BBA) - General Subjects, available at: https://doi.org/10.1016/j.bbagen.2026.130931 [Accessed 7 Aug. 2026].

Condividi e stampa

Salva la scheda, copia il link permanente o stampala in PDF.

Esporta riferimento

Esporta il record nei formati più comuni per usarlo con un gestore bibliografico.

Dettagli della risorsa

Informazioni bibliografiche utili per verificare che sia il materiale corretto.

Titolo
Exploring the role of sialidases in Galectin-1-associated resistance to cancer therapies
Autore / collaboratori
Scheidegger, Marco A. et al
Editore
Biochimica et Biophysica Acta (BBA) - General Subjects
Anno di pubblicazione
2026
ISSN
1872-8006
ISSN
1872-8006
Lingua
Español

Soggetti

Esplora risorse correlate a partire da questi soggetti.

Copiato